Table of Contents
MAPLE GROVE, Minn. – Upsher-Smith announced the recent launch of TORPENZ™ (everolimus) Tablets in 2.5 mg, 5 mg, 7.5 mg and 10 mg strengths. TORPENZ is an oral mTOR inhibitor used in patients with Tuberous Sclerosis Complex (TSC). Upsher-Smith’s TORPENZ (everolimus) Tablets are indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery and is also indicated in adult and pediatric patients aged 1 year and older with TSC for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
“As our specialty product portfolio continues to grow, Upsher-Smith remains committed to understanding the unique needs of rare disease communities and providing value-added services that ease access to critical medications,” said Jim Maahs, Vice President, Specialty & Rare Disease. “TORPENZ is the only everolimus backed our Promise of Support Program – a patient-centered initiative designed to offer patients, caregivers, and healthcare providers in the rare disease community comprehensive support throughout the treatment journey.”
The Upsher-Smith Promise of Support Program ensures timely and reliable access to specialty medications through customized services such bridge and starter medication supply. Through its partnership with specialty pharmacy, PANTHERx Rare, Upsher-Smith commits to providing a best-in-class experience for patients requiring rare disease medications, responding with urgency, and maintaining clear, open communication. It also includes copay assistance for eligible patients to help lessen the financial burden on patients and their families. To learn more about TORPENZ and the Upsher-Smith Promise of Support Program, visit www.torpenz.com.
%20tablets){kind=link}